Items where Division is "Faculties (pre 2018 reorg) > Faculty of Medicine (pre 2018 reorg) > Cancer Sciences (pre 2018 reorg)" and Year is 2024
 | Up a level |
Number of items: 13.
A
Risks of second primary cancers among 584,965 female and male breast cancer survivors in England: a 25-year retrospective cohort study - Isaac Allen, Hend Hassan and Yvonne Walburga
Type: Article
| 2024
E
ERCC1 abundance is an indicator of DNA repair-apoptosis decision upon DNA damage - Sule Erdemir, Rahul Sreekumar, Rahul Bhome, Alex Mirnezami, Tamer Yagci and A. Emre Sayan
Type: Article
| 2024
G
Targeted genetic sequencing analysis of 223 cases of pseudomyxoma peritonei treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy shows survival related to GNAS and KRAS status - Jane Gibson, Reuben J. Pengelly, Amatta Mirandari, Konstantinos Boukas, Sophia Stanford, Thomas Desmond Cecil, Faheez Mohamed, Sanjeev Paul Dayal, Alexios Tzivanakis, Brendan John Moran, Alex Mirnezami, Norman John Carr and Sarah Ennis
Type: Article
| 2024
J
Characterisation of the genomic landscape in splenic marginal zone lymphoma - Carolina Jaramillo Oquendo
Type: Thesis
| 2024
| University of Southampton
L
The potential clinical utility of Whole Genome Sequencing for patients with cancer: evaluation of a regional implementation of the 100,000 Genomes Project - Elaine Y.L. Leung, Helen L. Robbins, Shafquat Zaman, Neeraj Lal, Dion Morton, Lisa Dew, Anthony P. Williams, Yvonne Wallis, Jennie Bell, Manoj Raghavan, Gary Middleton and Andrew D. Beggs
Type: Article
| 2024
P
Proliferative history is a novel driver of clinical outcome in splenic marginal zone lymphoma - H. Parker, A. Mirandari and C.J. Oquendo
Type: UNSPECIFIED
| 2024
| medRxiv
| Item not available on this server.
R
Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial - Pasquale Rescigno, Nuria Porta and Laura Finneran
Type: Article
| 2024
T
Joint ABS-UKCGG-CanGene-CanVar consensus regarding the use of CanRisk in clinical practice - Olga Tsoulaki, Marc Tischkowitz, Antonis C. Antoniou, Hannah Musgrave, Gillian Rea, Ashu Gandhi, Karina Cox, Tracey Irvine, Sue Holcombe, Diana Eccles, Clare Turnbull, Ramsey Cutress, Stephanie Archer and Helen Hanson
Type: Article
| 2024
V
Machine learning to predict prostate artery embolization outcomes - G. Vigneswaran, N. Doshi, D. Maclean, T. Bryant, M. Harris, N. Hacking, K. Farrahi, M. Niranjan and S. Modi
Type: Article
| 2024
Cardiovascular comorbidities do not impact prostate artery embolisation (PAE) outcomes: retrospective analysis of the national UK-ROPE registry - Ganesh Vigneswaran, Drew Maclean, Neel Doshi, Mark Harris, Timothy J.C. Bryant, Nigel C. Hacking, Bhaskar Somani and Sachin Modi
Type: Article
| 2024
W
A preliminary phenomenological exploration of experiences of the empty pelvis syndrome derived from a modified-Delphi: the price of survival following pelvic exenteration for advanced pelvic cancer - Charles T. West, Andreas Denys, Sam A. Rose, Eva Pape, Gabrielle H. van Ramshorst, Paul A. Sutton, Hideaki Yano, Malcolm A. West, Alex H. Mirnezami, Lynn Calman and Samantha C. Sodergren
Type: Article
| 2024
Cardiopulmonary exercise variables and their association with postoperative morbidity and mortality after major oesophagogastric cancer surgery-a multicentre observational study - Malcolm A. West, Saqib Rahman, Sandy Jack, Michael P.W. Grocott and Denny Z.H. Levett
Type: Article
| 2024
Impact of isotype on the mechanism of action of agonist anti-OX40 antibodies in cancer: implications for therapeutic combinations - Jane Willoughby, Lang Dou and Sabyasachi Bhattacharya
Type: Article
| 2024